Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents [note 6] $ 35,853 $ 16,664
Prepaid expenses and other assets 1,122 670
Total current assets 36,975 17,334
Restricted cash [note 6] 50 50
Property and equipment, net [note 7] 42 57
Right-of-use assets [note 11] 146 329
Other assets [note 8] 187 187
License agreement [note 4 and 5] 1,864 2,087
Goodwill 1,034 1,034
Total assets 40,298 21,078
Current liabilities:    
Accounts payable 332 859
Accrued liabilities other 584 304
Accrued clinical liabilities 453 387
Accrued compensation 1,474 1,116
Current portion of long-term obligations [note 11] 92 203
Total current liabilities 2,935 2,869
Long-term obligations [note 11] 77 159
Total liabilities 3,012 3,028
Commitments and contingencies [note 11]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 6,111,735 and 1,474,258 issued and outstanding at December 31, 2020 and December 31, 2019, respectively. 76 41
Additional paid-in capital 97,640 63,709
Accumulated deficit (60,434) (45,704)
Accumulated other comprehensive income 4 4
Total stockholders' equity 37,286 18,050
Total liabilities and stockholders' equity 40,298 21,078
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value